FDA Approves Expanded Indications for Cerapedics' PearlMatrix Bone Graft Across All Major Lumbar Fusion Procedures
核心洞察
Cerapedics received FDA approval to expand PearlMatrix P-15 Peptide Enhanced Bone Graft (搜索) indications to include all major lumbar interbody fusion approaches, making it the only Class III drug-device spinal bone graft approved for comprehensive lumbar procedures.
The expansion follows the ASPIRE pivotal study published in Spine, which demonstrated statistically superior fusion speed and composite clinical success compared to local autograft (搜索) in transforaminal lumbar interbody fusion procedures.
PearlMatrix is now approved for use with titanium alloy and PEEK/titanium interbody fusion cages in addition to original PEEK cages, addressing the lumbar fusion market that represents approximately two-thirds of all fusion procedures.
Cerapedics Inc. announced that the U.S. Food and Drug Administration has approved an expansion to the indications for use and labeling for PearlMatrix P-15 Peptide Enhanced Bone Graft (搜索), a Class III drug-device combination product, for adult patients with degenerative disc disease (搜索) in the lumbar spine. The approval makes PearlMatrix the only Class III drug-device spinal bone graft approved for all major lumbar interbody surgical approaches.
Comprehensive Surgical Approach Coverage
With this label expansion, PearlMatrix is now approved for open or minimally invasive single-level anterior lumbar interbody fusion (ALIF), posterior lumbar interbody fusion (PLIF), oblique lumbar interbody fusion (OLIF), and lateral lumbar interbody fusion (LLIF), in addition to the original approval for transforaminal lumbar interbody fusion (TLIF) surgery. The product is also now approved for use with titanium alloy and PEEK/titanium interbody fusion cages cleared by the FDA for use in the lumbosacral spine, expanding beyond the original PEEK interbody fusion cages.
Lumbar fusion represents approximately two-thirds of the total fusion market, making this expansion clinically significant for addressing a substantial patient population. "With this label expansion, surgeons can now use PearlMatrix to help patients achieve faster fusion based on the interbody approach that meets their individual needs," the company stated.
Clinical Evidence Foundation
The expanded approval follows the initial FDA premarket approval of PearlMatrix in June 2025, which was supported by data from ASPIRE, a prospective, single-blinded, multicenter, randomized, controlled pivotal PMA IDE study. The ASPIRE study evaluated the safety and efficacy of PearlMatrix compared to local autograft (搜索) when applied in TLIF surgery, with results now published in Spine.
The study demonstrated statistical superiority with PearlMatrix versus the control in Composite Clinical Success as well as statistically superior fusion speed with comparable safety to local autograft (搜索). "The ASPIRE study was designed to include rigorous and clinically meaningful outcomes reflecting real-world practice to establish the safety and efficacy of PearlMatrix in single-level TLIF prior to pursuing expanded indications," according to the company.
Dr. Isaac L. Moss, Professor and Chair of Orthopedic Surgery at the University of Connecticut, noted that "The ASPIRE trial provides some of the most rigorous scientific evidence we have for any bone graft substitute on the market, as it demonstrated safety and improved time-to-fusion in both the overall and high risk-patient populations (i.e., patients with Type 2 diabetes (搜索), BMI ≥ 30 and/or nicotine users)."
Mechanism of Action and Product Profile
PearlMatrix P-15 Peptide Enhanced Bone Graft (搜索) is described as the first and only bone growth accelerator proven to accelerate lumbar fusion with demonstrated statistically superior fusion speed in single-level TLIF procedures. The active component, P-15 Peptide (搜索), is a 15 amino-acid sequence found naturally in Type-1 collagen (搜索), the predominant protein in bone.
The peptide serves as a powerful cell attachment factor in the bone regeneration process. Cerapedics' pharmaceutically manufactured P-15 Peptide (搜索) is bound onto calcium phosphate particles, creating a P-15-enhanced scaffold that provides attachment sites for osteogenic, bone-forming cells. Cell attachment activates pathways that release cell-signaling growth factors and allow bone growth through natural cellular processes.
Regulatory Timeline and Strategic Approach
The FDA approval for the expanded indications came within three months of submitting the supplemental application. "We strategically selected the TLIF approach for our ASPIRE study due to the complexity of the procedure to create a high bar of evidence before submitting our supplemental application to expand to other lumbar surgical approaches," said Valeska Schroeder, PhD, Chief Executive Officer of Cerapedics.
Clinical Indications and Considerations
PearlMatrix Bone Graft is indicated for intervertebral body fusion of the spine in skeletally mature patients and is intended for use at one level in the lumbar spine (L2-S1) for the treatment of degenerative disc disease (搜索) with up to Grade I spondylolisthesis (搜索). The system is to be used in patients who have had at least six months of non-operative treatment.
The product carries specific contraindications and warnings, including that it should not be used where there is an absence of load-bearing structural support at the graft site, sensitivity to components, active infection at the operative site, or sites subject to excessive impact or stress. The ASPIRE study noted that PearlMatrix in a TLIF procedure was associated with a higher rate of secondary surgical interventions compared to local autograft (搜索).
Market Context
Bone grafts, including Cerapedics' products, are used in over four million annual spine, orthopedics, trauma, and interventional procedures worldwide. Cerapedics has two FDA-approved drug-device products powered by its proprietary P-15 Osteogenic Cell Binding Peptide: PearlMatrix Bone Graft for lumbar interbody surgical approaches and i-FACTOR Bone Graft (搜索) for single-level anterior cervical discectomy and fusion in the cervical spine.